Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
25 years of interferon-based treatment of chronic hepatitis C : an epoch coming to an end
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 2833226
Author(s) Heim, Markus H
Author(s) at UniBasel Heim, Markus H.
Year 2013
Title 25 years of interferon-based treatment of chronic hepatitis C : an epoch coming to an end
Journal Nature reviews. Immunology
Volume 13
Number 7
Pages / Article-Number 535-42
Abstract Chronic hepatitis caused by infection with hepatitis C virus C (HCV) (therefore known as chronic hepatitis C (CHC)) is a leading cause of liver disease worldwide. For the past 25 years, recombinant interferon-alpha (IFNalpha) has been the main component of treatments for HCV infection. Treatment efficacy has shown a stepwise improvement following the pegylation of IFNalpha and its use in combination with other antiviral drugs. However, viral escape mechanisms, refractory IFNalpha signalling in the liver and substantial drug toxicity still limit the efficacy of this treatment. A new generation of HCV-specific antiviral drugs will probably improve response rates and might replace IFNs in CHC treatment in the next few years. This Timeline article summarizes the history of CHC treatment using recombinant IFNalpha with an emphasis on the mechanisms of action and the causes of non-response.
Publisher Nature Publishing Group
ISSN/ISBN 1474-1733
edoc-URL http://edoc.unibas.ch/dok/A6338533
Full Text on edoc No
Digital Object Identifier DOI 10.1038/nri3463
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/23743475
ISI-Number WOS:000320853100013
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.325 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
20/04/2024